<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Sareum Holdings Plc — News on 6ix</title>
    <link>https://6ix.com/company/sareum-hldgs-plc</link>
    <description>Latest news and press releases for Sareum Holdings Plc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 12 Mar 2026 07:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/sareum-hldgs-plc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835eb7178dffbe2df12aae6.webp</url>
      <title>Sareum Holdings Plc</title>
      <link>https://6ix.com/company/sareum-hldgs-plc</link>
    </image>
    <item>
      <title>Half-Year Report for Six Months Ended 31 Dec 2025</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/half-year-report-for-six-months-ended-31-dec-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/half-year-report-for-six-months-ended-31-dec-2025</guid>
      <pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC reported its unaudited half-year results for the six months ended 31 December 2025, with a loss before tax of £1.9 million and cash reserves of £2.5 million. The company has restarted the Phase 2-enabling toxicology programme for its lead autoimmune disease candidate, SDC-1801, following positive Phase 1 data and a sufficient cash runway. Preparations are underway to partner SDC-1802, a cancer immunotherapy asset, and SRA737, a cancer drug, with improved licensing terms for S</description>
    </item>
    <item>
      <title>Restart of Phase 2-enabling toxicology programme</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/restart-of-phase-2-enabling-toxicology-programme</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/restart-of-phase-2-enabling-toxicology-programme</guid>
      <pubDate>Tue, 17 Feb 2026 07:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC has restarted the Phase 2-enabling toxicology programme for its selective TYK2/JAK1 inhibitor, SDC-1801, which is being developed for autoimmune diseases like psoriasis. This programme, being conducted by a global contract research organisation using existing cash resources and toxicology batch, is expected to complete its dosing phase by mid-2026 and the full Phase 2-enabling package by year-end, following preliminary pharmacokinetic work. The company is confident that this,</description>
    </item>
    <item>
      <title>Results of AGM</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/results-of-agm-28</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/results-of-agm-28</guid>
      <pubDate>Tue, 09 Dec 2025 16:25:00 GMT</pubDate>
      <description>Sareum Holdings PLC announced that all resolutions were duly passed at its Annual General Meeting, including the receipt of financial statements with 97.7% of votes in favour, approval of the Directors&apos; Remuneration Report with 87.7% in favour, and the re-election of Mr John Reader as Director with 91.9% in favour. The re-appointment of auditors and authorization for the audit committee to determine auditor remuneration also received strong support, with 97.4% and 92.3% of votes respectively. Re</description>
    </item>
    <item>
      <title>Annual General Meeting Statement</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/annual-general-meeting-statement-2</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/annual-general-meeting-statement-2</guid>
      <pubDate>Tue, 09 Dec 2025 07:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC provided an update ahead of its Annual General Meeting, highlighting progress on its lead candidate SDC-1801, which completed Phase 1 trials and demonstrated favorable safety and pharmacokinetic profiles, with Phase 2 enabling toxicology studies set to restart in Q1 2026 following the appointment of a new contract research organisation. The company also reported completing translational studies for SDC-1802, with a focus on haematological cancers, and has renegotiated signifi</description>
    </item>
    <item>
      <title>Notice of AGM, Annual Report and Accounts</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/notice-of-agm-annual-report-and-accounts-1</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/notice-of-agm-annual-report-and-accounts-1</guid>
      <pubDate>Mon, 17 Nov 2025 07:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC has announced its Annual General Meeting will be held on Tuesday, December 9, 2025, at 10:00 AM GMT, with online access provided via the Investor Meet Company platform. Shareholders are encouraged to submit questions in advance by December 8, 2025, and to submit proxy votes early, as online voting will not be available at the meeting. The company will also be distributing its annual report and accounts for the year ended June 30, 2025, to shareholders who requested a hard cop</description>
    </item>
    <item>
      <title>Appointment of Joint Corporate Broker</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/appointment-of-joint-corporate-broker-34</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/appointment-of-joint-corporate-broker-34</guid>
      <pubDate>Thu, 30 Oct 2025 07:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC announced the appointment of Singer Capital Markets as Joint Corporate Broker, effective immediately. Strand Hanson Limited will remain the company&apos;s Nominated Adviser. Oberon Capital will also continue its role as Joint Corporate Broker. The company is a clinical-stage biotechnology company focused on developing next-generation kinase inhibitors for autoimmune disease and cancer. Sareum&apos;s lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1 and is a potential trea</description>
    </item>
    <item>
      <title>Preliminary Results for Year Ended 30 June 2025</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/preliminary-results-for-year-ended-30-june-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/preliminary-results-for-year-ended-30-june-2025</guid>
      <pubDate>Thu, 23 Oct 2025 06:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC reported a loss before tax of £3.06 million for the year ended 30 June 2025. The company&apos;s cash reserves increased to £3.5 million, up from £1.5 million the previous year, bolstered by successful fundraises. Administrative expenses, including R&amp;D, totaled £3.38 million, with R&amp;D spending specifically at £2.07 million. R&amp;D tax credits received during the period amounted to £1.2 million, compared to £0.8 million in the prior year. The company renegotiated improved economic term</description>
    </item>
    <item>
      <title>Update on toxicology study for SDC-1801</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/update-on-toxicology-study-for-sdc-1801</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/update-on-toxicology-study-for-sdc-1801</guid>
      <pubDate>Fri, 10 Oct 2025 06:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC has discontinued its 16-week GLP preclinical toxicology study for SDC-1801 after unexpected safety findings emerged. The issues disproportionately affected the control group, which received an inactive dosing solution, suggesting the findings are unlikely related to SDC-1801. Dosing has been terminated, and the study will be formally closed after scheduled analyses. Sareum is reviewing data with experts to determine the cause and next steps and is in discussions with alternat</description>
    </item>
    <item>
      <title>Notice of Results and Investor Presentation</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/notice-of-results-and-investor-presentation-36</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/notice-of-results-and-investor-presentation-36</guid>
      <pubDate>Tue, 07 Oct 2025 06:00:00 GMT</pubDate>
      <description>Sareum Holdings PLC will announce its financial results for the year ended June 30, 2025, on Thursday, October 23, 2025. The company will also host a live investor presentation on the same day at 14:00 BST via the Investor Meet Company platform. The presentation is open to all existing and potential shareholders, who can submit questions in advance until October 22, 2025, at 09:00 BST, or during the live presentation. A copy of the presentation will be available on the company&apos;s website followin</description>
    </item>
    <item>
      <title>Exercise of Warrants</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/exercise-of-warrants-24</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/exercise-of-warrants-24</guid>
      <pubDate>Fri, 26 Sep 2025 14:12:00 GMT</pubDate>
      <description>Sareum Holdings PLC announced the exercise of warrants to subscribe for 20,200 new ordinary shares at 12.5 pence per share, resulting in a total consideration of £2,525 for the company. Application has been made for admission of these shares to trading on AIM, expected around October 2, 2025. Following admission, the total number of ordinary shares in issue will be 138,065,173, representing the total number of voting rights.

                Disclaimer*</description>
    </item>
    <item>
      <title>Sareum Collaboration with Receptor.AI</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/sareum-collaboration-with-receptorai</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/sareum-collaboration-with-receptorai</guid>
      <pubDate>Tue, 12 Aug 2025 06:00:00 GMT</pubDate>
      <description>Sareum Collaboration with Receptor.AI.</description>
    </item>
    <item>
      <title>Appointment of Sole Broker</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/appointment-of-sole-broker-3</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/appointment-of-sole-broker-3</guid>
      <pubDate>Fri, 04 Jul 2025 06:00:00 GMT</pubDate>
      <description>Appointment of Sole Broker.</description>
    </item>
    <item>
      <title>Initiation of Toxicology Studies for SDC-1801</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/initiation-of-toxicology-studies-for-sdc-1801</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/initiation-of-toxicology-studies-for-sdc-1801</guid>
      <pubDate>Thu, 29 May 2025 06:00:00 GMT</pubDate>
      <description>Initiation of Toxicology Studies for SDC-1801.</description>
    </item>
    <item>
      <title>Update on TYK2/JAK1 and SRA737 Programmes</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/update-on-tyk2jak1-and-sra737-programmes</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/update-on-tyk2jak1-and-sra737-programmes</guid>
      <pubDate>Mon, 28 Apr 2025 06:00:00 GMT</pubDate>
      <description>Update on TYK2/JAK1 and SRA737 Programmes.</description>
    </item>
    <item>
      <title>Director’s Dealing</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/directors-dealing-23</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/directors-dealing-23</guid>
      <pubDate>Thu, 27 Mar 2025 07:00:00 GMT</pubDate>
      <description>Director’s Dealing.</description>
    </item>
    <item>
      <title>Sareum Half-Year Report</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/sareum-half-year-report</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/sareum-half-year-report</guid>
      <pubDate>Tue, 25 Mar 2025 07:00:00 GMT</pubDate>
      <description>Sareum Half-Year Report.</description>
    </item>
    <item>
      <title>Notice of HY Results and Investor Presentation</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/notice-of-hy-results-and-investor-presentation-1</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/notice-of-hy-results-and-investor-presentation-1</guid>
      <pubDate>Thu, 20 Mar 2025 07:00:00 GMT</pubDate>
      <description>Notice of HY Results and Investor Presentation.</description>
    </item>
    <item>
      <title>Institutional Equity Fundraise</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/institutional-equity-fundraise</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/institutional-equity-fundraise</guid>
      <pubDate>Thu, 13 Mar 2025 07:15:00 GMT</pubDate>
      <description>Institutional Equity Fundraise.</description>
    </item>
    <item>
      <title>Sareum Acquires Licence for SRA737</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/sareum-acquires-licence-for-sra737</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/sareum-acquires-licence-for-sra737</guid>
      <pubDate>Thu, 13 Mar 2025 07:08:00 GMT</pubDate>
      <description>Sareum Acquires Licence for SRA737.</description>
    </item>
    <item>
      <title>Update on SRA737</title>
      <link>https://6ix.com/company/sareum-hldgs-plc/news/update-on-sra737</link>
      <guid isPermaLink="true">https://6ix.com/company/sareum-hldgs-plc/news/update-on-sra737</guid>
      <pubDate>Tue, 31 Dec 2024 07:00:00 GMT</pubDate>
      <description>Update on SRA737.</description>
    </item>
  </channel>
</rss>